Thorsten Langer

CNS late‐effects after ALL therapy in childhood. Part III: Neuropsychological performance in long‐term survivors of childhood ALL: Impairments of concentration, attention, and memory*†‡

Thorsten Langer, Peter Martus, Holger Ottensmeier et al. · Medical and Pediatric Oncology · 2002 · 174 citations

Medicine, Oncology, Pediatrics +13

High-dose methotrexate in pediatric acute lymphoblastic leukemia: Impact of ABCC2 polymorphisms on plasma concentrations

Tilman T. Rau, B ERNEY, Ralf Göres et al. · Clinical Pharmacology & Therapeutics · 2006 · 171 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +17

Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia

Susanne Radtke, Oliver Zolk, Bertold Renner et al. · Blood · 2013 · 170 citations

Pharmacy, Genetics, Pharmacokinetics +16

Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany

Astrid Pechmann, Thorsten Langer, David Schorling et al. · Journal of Neuromuscular Diseases · 2018 · 149 citations · Full text

Medicine, Neurology, Neuromuscular Disorders +14

CNS late effects after ALL therapy in childhood. Part I: Neuroradiological findings in long-term survivors of childhood ALL—an evaluation of the interferences between morphology and neuropsychological performance

Holger Hertzberg, W. Huk, Michael A. Ueberall et al. · Medical and Pediatric Oncology · 1997 · 114 citations

Medicine, Pediatrics, Radiology +17